

## 2021

1. Kato M, Kobayashi T, Matsui Y, Ito K, Hikami K, Yamada T, Ogawa K, Nakamura K, Sassa N, Yokomizo A, Abe T, Tsuchihashi K, Tatarano S, Inokuchi J, Tomida R, Fujiwara M, Takahashi A, Matsumoto K, Shimizu K, Araki H, Kurahashi R, Ozaki Y, Tashiro Y, Uegaki M, Kojima T, Uchida J, Ogawa O, Nishiyama H, Kitamura H, Japan Urological Oncology Group: **Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab.** *Int J Urol.* 2021 Dec; **28** (12): 1261-1267. [5y-IF: 3.011]
2. Konno M, Osawa T, Hotta K, Shimizu A, Abe T, Matsumoto R, Kikuchi H, Shinohara N: **Primary renal leiomyosarcoma with a tumor thrombus in the inferior vena cava.** *IJU Case Rep.* 2021 Nov; **5** (1): 66-69. [5y-IF: N/A]
3. Nishioka K, Gotoh K, Hashimoto T, Abe T, Osawa T, Matsumoto R, Yokota I, Katoh N, Kinoshita R, Yasuda K, Yakabe T, Yoshimura T, Takao S, Shinohara N, Aoyama H, Shimizu S, Shirato H: **Are simple verbal instructions sufficient to ensure that bladder volume does not deteriorate prostate position reproducibility during spot scanning proton therapy?** *BJR Open.* 2021 Nov; **3** (1): 20210064. [5y-IF: N/A]
4. Nishioka K, Gotoh K, Hashimoto T, Abe T, Osawa T, Matsumoto R, Yokota I, Katoh N, Kinoshita R, Yasuda K, Yakabe T, Yoshimura T, Takao S, Shinohara N, Aoyama H, Shimizu S, Shirato H: **Are simple verbal instructions sufficient to ensure that bladder volume does not deteriorate prostate position reproducibility during spot scanning proton therapy?** *BJR Open.* 2021 Nov; **3** (1): 20210064. [5y-IF: N/A]
5. Takeda H, Matsumoto R, Takakuwa E, Hori K, Moriguchi T, Yamada S, Kikuchi H, Osawa T, Abe T, Shinohara N: **Favorable response to pembrolizumab in granulocyte colony-stimulating factor-producing upper urinary tract urothelial carcinoma.** *IJU Case Rep.* 2021 Dec; **5** (2): 108-112. [5y-IF: N/A]

## 2022

1. Aydın A, Ahmed K, Abe T, Raison N, Van Hemelrijck M, Garmo H, Ahmed HU, Mukhtar F, Al-Jabir A, Brunckhorst O, Shinohara N, Zhu W, Zeng G, Sfakianos JP, Gupta M, Tewari A, Gözen AS, Rassweiler J, Skolarikos A, Kunit T, Knoll T, Moltzahn F, Thalmann GN, Lantz Powers AG, Chew BH, Sarica K, Shamim Khan M, Dasgupta P SIMULATE Trial Group: **Effect of Simulation-based Training on Surgical Proficiency and Patient Outcomes: A Randomised Controlled Clinical and Educational Trial.** *Eur Urol.* 2022 Apr; **81** (4): 385-393. [5y-IF: 21.729]
2. Ebina K, Abe T, Hotta K, Higuchi M, Furumido J, Iwahara N, Kon M, Miyaji K, Shibuya S, Lingbo Y, Komizunai S, Kurashima Y, Kikuchi H, Matsumoto R, Osawa T, Murai S, Tsujita T, Sase K, Chen X,

- Konno A, Shinohara N: **Objective evaluation of laparoscopic surgical skills in wet lab training based on motion analysis and machine learning.** *Langenbecks Arch Surg.* 2022 Aug; **407** (5): 2123-2132. [5y-IF: 3.116]
3. Hirata Y, Higuchi M, Osawa T, Hinotsu S, Harabayashi T, Mochizuki T, Enami N, Nounaka O, Shinno Y, Kikuchi H, Matsumoto R, Abe T, Murai S, Shinohara N: **Late recurrence in patients with non-muscle-invasive bladder cancer after 5-year cancer-free periods.** *Int J Urol.* 2022 Oct; **29** (10): 1140-1146. [5y-IF: 3.011]
  4. Kikuchi H, Osawa T, Matsumoto R, Abe T, Maruyama S, Harabayashi T, Miyata H, Kashiwagi A, Ikeshiro S, Sazawa A, Fukui R, Morita K, Takeuchi I, Hori K, Yamashita N, Minami K, Mochizuki T, Murai S, Shinohara N: **Efficacy of nivolumab plus ipilimumab as first-line therapy for primary tumors in patients with renal cell carcinoma.** *Urol Oncol.* 2022 Jan; **40** (1): 13.e19-13.e27. [5y-IF: 3.011]
  5. Kikuchi H, Abe T, Matsumoto R, Osawa T, Maruyama S, Murai S, Shinohara N: **Outcomes of bacillus Calmette-Guérin therapy without a maintenance schedule for high-risk non-muscle-invasive bladder cancer in the second transurethral resection era.** *Int J Urol.* 2022 Mar; **29** (3): 251-258. [5y-IF: 3.011]
  6. Kita Y, Ito K, Kanda S, Joraku A, Yamaguchi R, Shimizu Y, Hayata N, Somiya S, Shibasaki N, Kimura T, Hikami K, Yamada T, Abe T, Tsuchihashi K, Tatarano S, Nishiyama H, Kitamura H, Kobayashi T: **Tolerability and treatment outcome of pembrolizumab in patients with advanced urothelial carcinoma and severe renal dysfunction.** *Urol Oncol.* 2022 Sep; **40** (9): 410.e11-410.e18. [5y-IF: 3.099]
  7. Kobayashi K, Matsuyama H, Kawai T, Ikeda A, Miyake M, Nishimoto K, Matsushita Y, Komura K, Abe T, Kume H, Nishiyama H, Fujimoto K, Oyama M, Miyake H, Inoue K, Mitsui T, Kawakita M, Ohyama C, Mizokami A, Kuroiwa H: **Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study).** *Int J Urol.* 2022 Jul; **29** (7): 632-638. [5y-IF: 3.011]
  8. Ebina K, Abe T, Hotta K, Higuchi M, Furumido J, Iwahara N, Kon M, Miyaji K, Shibuya S, Lingbo Y, Komizunai S, Kurashima Y, Kikuchi H, Matsumoto R, Osawa T, Murai S, Tsujita T, Sase K, Chen X, Konno A, Shinohara N: **Automatic assessment of laparoscopic surgical skill competence based on motion metrics.** *PLoS One.* 2022 Nov; **17** (11): e0277105. [5y-IF: 4.069]
  9. Miyata H, Hirohashi Y, Yamada S, Yanagawa J, Murai A, Hashimoto S, Tokita S, Hori K, Abe T, Kubo T, Tsukahara T, Kanaseki T, Shinohara N, Torigoe T: **GRIK2 is a target for bladder cancer stem-like cell-targeting immunotherapy.** *Cancer Immunol Immunother.* 2022 Apr; **71** (4): 795-806. [5y-IF: 6.693]
  10. Murakami Y, Matsumoto K, Miyake M, Amano N, Shimura S, Nishimura N, Iida K, Matsushita Y, Abe T, Yamada T, Uemura M, Matsui Y, Taoka R, Kojima T, Kobayashi T, Nishiyama N, Kitamura H, Nishiyama H, Fujimoto K: **Real-world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer.** *Int J Urol.* 2022 Jul 20; doi: 10.1111/iju.14976. [5y-IF: 3.011]
  11. Narita H, Takenaka J, Watanabe S, Abe T, Kudo K: **Retroperitoneal Chronic Expanding Hematoma**

**Mimicking Malignancy on FDG PET/CT.** *Clin Nucl Med.* 2022 Sep; **47** (9): e591-e593. [5y-IF: 7.77]

12. Oishi Y, Kitta T, Osawa T, Abe T, Shinohara N, Nosato H, Sakanashi H, Murakawa M: **Diagnosis and Localization of Prostate Cancer via Automated Multiparametric MRI Equipped with Artificial Intelligence.** *Uro.* 2022 **2** (1): 21-29. [5y-IF: N/A]
13. Osawa T, Abe T, Kikuchi H, Matsumoto R, Murai S, Nakao T, Tanaka S, Watanabe A, Shinohara N: **Validation of an online application to identify potential immune-related adverse events associated with immune checkpoint inhibitors based on the patient's symptoms.** *PLoS One.* 2022 Mar; **17** (3): e0265230. [5y-IF: 4.069]
14. Suzuki M, Miyaji K, Watanabe R, Suzuki T, Matoba K, Nakazono A, Nakamaru Y, Konno A, Psaltis AJ, Abe T, Homma A, Wormald PJ: **Repetitive simulation training with novel 3D-printed sinus models for functional endoscopic sinus surgeries.** *Laryngoscope Investig Otolaryngol.* 2022 Jul; **7** (4): 943-954. [5y-IF: 2.857]
15. Takayanagi A, Kato F, Nozaki A, Matsumoto R, Osawa T, Kuwahara K, Matsuno Y, Asano H, Kato T, Watari H, Abe T, Shinohara N, Kudo K: **Imaging findings of ovarian metastasis of primary renal cell carcinoma: A case report and literature review.** *Radiol Case Rep.* 2022 May; **17** (7): 2320-2327. [5y-IF: N/A]
16. Tohi Y, Kato T, Yokomizo A, Mitsuzuka K, Tomida R, Inokuchi J, Matsumoto R, Saito T, Sasaki H, Inoue K, Kinoshita H, Fukuhara H, Maruyama S, Sakamoto S, Tanikawa T, Egawa S, Ichikura H, Abe T, Nakamura M, Kakehi Y, Sugimoto M: **Impact of health-related quality of life on repeat protocol biopsy compliance on active surveillance for favorable prostate cancer: results from a prospective cohort in the PRIAS-JAPAN study.** *Urol Oncol.* 2022 Feb; **40** (2): 56.e9-56.e15. [5y-IF: 3.099]
17. Yamada S, Abe T, Sazawa A, Katano H, Suzuki H, Takeuchi I, Ishizaki J, Minami K, Morita K, Tsuchiya K, Takada N, Maru S, Ishikawa S, Sato S, Kawazu T, Yamashita T, Ono T, Mochizuki T, Akino T, Sasaki Y, Shinno Y, Furumido J, Miyata H, Kikuchi H, Matsumoto R, Osawa T, Shinohara N: **Comparative study of postoperative complications after radical cystectomy during the past two decades in Japan: Radical cystectomy remains associated with significant postoperative morbidities.** *Urol Oncol.* 2022 Jan; **40** (1): 11.e17-11.e25. [5y-IF: 3.099]
18. Yamagata Y, Abe T, Iwahara N, Takada K, Hida Y, Takakuwa E, Kikuchi H, Matsumoto R, Osawa T, Shinohara N: **Metastatic neuroendocrine carcinoma of right adrenal glands successfully treated with laparoscopic adrenalectomy after multimodal therapy.** *IJU case reports.* 2022 July; doi: <https://doi.org/10.1002/iju5.12511>. [5y-IF: N/A]

